AMSTERDAM – Despite the transformative impact of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV), reimbursement for the drugs still faces "considerable restrictions" in Europe, according to research presented Thursday at the International Liver Congress, suggesting that an early challenge for key drugmakers in the space, such as Gilead Sciences Inc. and Abbvie Inc., still endures.